February 18, 2026

How Should Biotechs Correct “Mistakes” in Analysts’ Equity Reports?

Few things irritate a biotech’s management team more than reading an analyst note the morning after a major event and thinking: that’s not right.

Sometimes it’s a genuine factual error – the wrong patient number, the wrong endpoint definition, a misread of guidance or an incorrect cash runway assumption. But more often, what management labels a “mistake” is actually something else: a difference of opinion.

Biotechs are, by nature, optimistic. They have to be. They are building a company around future events not yet proven. Equity analysts, by contrast, are paid to be measured and conservative, to pressure-test assumptions, and to protect their credibility with investors. If the company is bullish and the analyst is cautious, that is not a “mistake.” That is the market doing its job.

The goal of IR is not to win the argument. It is to ensure the market is working from accurate information – while preserving relationships with the analysts who help interpret your story.

Step 1: Triage – factual error or interpretation?

Before you pick up the phone, ask a simple question: Is this objectively wrong, or just framed differently than we would like?

A factual error might include:

• Incorrect trial design details (randomization, endpoints, population).
• Misstated regulatory status or timelines.
• Wrong balance sheet figures, dilution assumptions, or share count.
• A quote attributed incorrectly to management.

A difference of opinion might include:

• A conservative probability-of-success estimate.
• A discounted view on commercial uptake.
• Skepticism on comparability versus competitors.
• A lower peak sales assumption than management’s internal view.

Only the first category warrants “correction.” The second category warrants engagement, not confrontation.

Step 2: Be mindful: analysts are prideful of their work.

Equity analysts live on reputation. Their research is their product, and they tend to be (understandably) prideful about it. If you approach them in a way that sounds like “you got it wrong,” you may trigger defensiveness, even if you are “right.”

The objective is to get to an updated note or a clarified view without damaging the relationship.

Tone matters. Words matter. “Mistake” is rarely the right word to use, even internally.

Step 3: Correct privately, quickly, and surgically.

If it is a true factual error, the best approach is usually direct and private:

• Email or call the analyst promptly (same day if possible).
• Identify the specific item and the correct fact – with a source (slide page, press release line, 10-Q table).
• Keep your focus narrow – try and deal with one issue at a time (do not send a laundry list).
• Avoid editorializing or debating valuation.

For example: “Just flagging one point: the Phase 2 cohort size was 48, not 38 – see slide 12 of our Corporate Deck (attached). Everything else in your note looked fair.”

This makes it easy for the analyst to fix. It also communicates professionalism: you are not trying to rewrite their work; you are ensuring accuracy.

Step 4: Never ask for a rating change.

Nothing will poison an analyst relationship faster than implying the company expects a certain price target or recommendation. Even if the analyst is wrong on a fact, your job is to correct the fact – not to weaponize the correction into a demand for a more bullish conclusion.

If you want the analyst to be more constructive, the right lever is better information over time, not pressure in the moment.

Step 5: If the issue is opinion, broaden the education.

When the disagreement is interpretive, consider:

• Offering additional context on why you view the outcome differently.
• Suggesting a follow-up call with management to walk through assumptions.
• Providing more explicit guidance or milestone clarity in future communications.

But accept that the analyst may still disagree. Analysts are allowed to be conservative  –  and sometimes they are right to be.

Step 6: Know when to escalate (which is rarely).

If a factual error is material and the analyst refuses to correct it, you may need to broaden the fix:

• Clarify publicly in an FAQ on your IR site.
• Address it in your next investor call Q&A.
• Ensure future materials pre-empt confusion.

Public escalation should be a last resort. Otherwise, you risk the cure being worse than the disease.

In summary, most “mistakes” in analysts’ reports are, in fact, not mistakes at all – they are differences in risk tolerance and interpretation. When there is a true factual error, correct it quickly, privately, and professionally. Respect the analyst’s pride, avoid confrontation, and keep the relationship intact.